Evaluation of the Effect of Age-Related Macular Degeneration Type And Stage on the Risk of Parkinson’s Disease

Year 2024, Volume: 46 Issue: 3, 422 - 428, 27.05.2024

Erdoğan Yaşar Ugur Gürlevik Mustafa Değer Bilgeç Muzaffer Güneş

https://doi.org/10.20515/otd.1420279

Abstract

The aim of the study was to investigate the distance between Parkinson's Disease (PD) and Age-Related Macular Degeneration (AMD) type and stage.. Our prospective study, the dry-type AMD group consisted of 296 patients with early and 284 patients with late-stage. The neovascular AMD group included 285 early and 277 late-stage patients. The control group consisted of 300 patients. AMD patients were grouped as dry and neovascular type and early and late stage. The patients were questioned about the use of drugs for PD, and the use was recorded as having the disease. If any of the complaints seen in the PD were present, the patient was referred to a neurologist. PD was detected in 1% of the control group and 4.6% in the neovascular type AMD group, and this difference was significant (p:0.04). This difference was present in both the early (%4.5) and late-stage (%4.6 ) (p:0.04, p:0.04). PD was determined 3.78 times greater among neovascular AMD patients(p:0.03), and significant association was present in both early (3.72 times) and late-stage (3.82 times) (p:0.03, p:0.03). In the dry-type AMD group 2.7% PD was detected and there was no statistical difference (p>0.05). This difference was not significant in the early stage (%2.3) or late-stage (%2.8) and also there was no association with dry-type AMD (p>0.05). Also, unilateral and bilateral involvement in AMD was not associated with PD (p>0.05). Our study revealed the association between both early and late neovascular AMD and PD. However, any significant relationship was not detected in terms of both unilateral and bilateral involvement.

Keywords

Age-related Macular Degeneration, Parkinson, prevalence, stage, type

Ethical Statement

The study was approved by the Ethics Committee of University Hospital with the number 2022/04-05

Yaşa Bağlı Makula Dejenerasyonu Tipi Ve Evresinin Parkinson Hastalığı Riskine Etkisinin Değerlendirilmesi

Abstract

Çalışmamızın amacı Parkinson Hastalığı (PD) ile Yaşa Bağlı Makula Dejenerasyonu (YBMD) tipi ve evresi arasındaki ilişkiyi araştırmak idi.. Prospektif çalışmamızda kuru tip YBMD grubu 296 erken evre ve 284 geç evre hastadan oluşuyordu. Neovasküler AMD grubu 285 erken ve 277 geç evre hastayı içeriyordu. Kontrol grubu 300 hastadan oluşuyordu. YBMD hastaları kuru ve neovasküler tip ile erken ve geç evre olarak gruplandırıldı. Hastalara PH için ilaç kullanımı sorgulandı ve kullananların hastalıklı olduğu kaydedildi. PH'de görülen şikayetlerden herhangi birinin mevcut olması durumunda hasta nöroloji uzmanına yönlendirildi. Kontrol grubunun %1'inde, neovasküler tip YBMD grubunda ise %4,6 oranında PH saptandı ve bu fark anlamlıydı (p:0,04). Bu fark hem erken (%4,5) hem de geç dönemde (%4,6) mevcuttu (p:0,04, p:0,04). Neovasküler YBMD hastalarında PD 3,78 kat daha fazla saptandı (p:0,03), hem erken (3,72 kat) hem de geç dönemde (3,82 kat) anlamlı ilişki mevcuttu (p:0,03, p:0,03). Kuru tip YBMD grubunda %2,7 PD tespit edildi ve istatistiksel olarak fark saptanmadı (p>0,05). Bu fark erken dönemde (%2,3) ve geç dönemde (%2,8) anlamlı bulunmazken, kuru tip YBMD ile de ilişki saptanmadı (p>0,05). Ayrıca YBMD'nin tek taraflı ve iki taraflı tutulumu PH ile ilişkili değildi (p>0,05). Çalışmamız hem erken hem de geç neovasküler YBMD ile PD arasındaki ilişkiyi ortaya çıkardı. Ancak hem tek taraflı hem de iki taraflı tutulum açısından anlamlı bir ilişki saptanmadı.

Keywords

Yaşa Bağlı Makula Dejenerasyonu, Parkinson hastalığı, prevalans, evre, tip

Ethical Statement

Çalışma Aksaray Üniversitesi Hastanesi Etik Kurulu tarafından 2022/04-05 numarası ile onaylandı.

References

• 1. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
• 2. Garcia-Garcia J, Usategui-Martin R, Sanabria MR, Fernandez-Perez E, Telleria JJ, Coco-Martin RM. Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment. Ophthalmic Res 2022; 65(6):615-636.
• 3. Vyawahare H, Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Cureus 2022; 14(9):e29583.
• 4. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proceed Nat Sci 2002;99(18),11830-11835
• 5. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye 1994; 8: 269-83.
• 6. Curcio C, Leigh Millican C. Basal linear deposit and large drusen are specific for age-related maculopathy. Arch Ophthalmol 1997;117: 329-339
• 7. Kulkarni AD, Kuppermann B. Neovascular age-related macular degeneration. Adv Drug Deliv Rev. 2005;57(14): 1994–2009.
• 8. Sulzbacher F, Kiss C, Kaider A, Eisenkoelbl S, MunkM, Roberts P, Schmidt-Erfurth U. Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2012; 8: 23
• 9. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007; 68(5):326-337.
• 10. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature reviews Disease primers. 2017;23(3):17013.
• 11. Rajan S, Kaas B. Parkinson's Disease: Risk Factor Modification and Prevention. Semin Neurol 2022;42(5):626-638.
• 12. Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’sdiseaseacross North America. NPJ Parkinsons Dis 2018; 4:21.
• 13. Cao S, Cui Y, Jin J, Li F, Liu X, Feng T. Prevalence of axial postural abnormalities and their subtypes in Parkinson's disease: a systematic review and meta-analysis. J Neurol. 2023;270(1):139-151.
• 14. Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis. Trends in neurosciences. 2019;42(1):4–13.
• 15. Ding X, Patel M, Chan CC. Molecular pathology of age- related macular degeneration. Prog Retin Eye Res 2009;28(1):1–18.
• 16. Chung SD, Ho JD, Hu CC, Lin HC, Sheu JJ. Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study. Am J Ophthalmol 2014;157(2):464-469.
• 17. Chen PJ, Wan L, Lai JN, Chen CS, Chen JJ, Yen WM, et al. Increased risk of Parkinson's disease among patients with age-related macular degeneration. BMC Ophthalmol 2021;21(1):426.
• 18. Choi S, Jahng WJ, Park SM, Jee D. Association of Age-Related Macular Degeneration on Alzheimer or Parkinson Disease: A Retrospective Cohort Study. Am J Ophthalmol 2020;210:41-47.
• 19. Etminan M, Samii A, He B. Risk of Parkinson’s disease in patients with neovascular age-related macular degeneration. J Curr Ophthalmol 2018; 30(4), 365-367.
• 20. Patil H, Saha A, Senda E, Cho KI, Haque M, Yu M &Ferreira PA.Selective impairment of a subset of ran- GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation. J Biol Chem 2014;289(43):29767e29789.
• 21. Telander DG. Infammation and age-related macular degeneration (AMD). Semin Ophthalmol 2011;26(3):192–7.
• 22. Pajares M, Rojo AI, Manda G, Boscá L, Cuadrado A. Infammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 2020;9(7):1687
• 23. De Jong PT. Age-related macular degeneration. N Engl J Med 2006;355(14):1474–85.
• 24. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003;39(6):889–909.
• 25. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem Res 2009; 34(1):55–65.
• 26. Beatty S, Koh H-H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45(2):115–34.
• 27. Balk LJ, Petzold A, Oberwahrenbrock T, Brandt AU, Albrecht P. Distribution of retinallayeratrophy in patients with Parkinson disease and association with disease severity and duration. Am J Ophthalmol 2014;158(4):845.
• 28. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31(11):2473e2475.
• 29. Figueroa AG, Boyd BM, Christensen CA, Javid CG, McKay BS, Fagan TC, et al. Levodopa positivelyafects neovascular age –related macular degeneration. Am J Med 2021;134(1):122–128.e123